$53.05
1.22 (+2.35%)
Celgene Corp (CELG)
CAPS Rating:
A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
RSS Headlines
Fool UK
Recs
I want to take advantage of the downturn and pick up some quality stocks at depressed prices, but I don't want to sacrifice my pure biotech profile. Therefore, I'm branching out into large profitable biotech companies even though I don't really have the capability to valuate them based on traditional metrics. Vidaza should assume a larger share of the MDS market now that they have established a mortality benefit and Supergen's Dacogen failed to do the same. Between that and historical performance I'm hoping for 10-20 points from this pick.
I think I'll take a positive accuracy and stop fighting the S&P on this pick. I'm looking for a broad market pullback and the large cap biotechs should go with it.